List of Medications for Diabetes

This comprehensive listing includes antihyperglycemic agents that can be used for glycemic control in diabetes.


New Antihyperglycemics
Class Generic/Brand/Approval year
SGLT-2 inhibitor Canagliflozin (Invokana), 2013
DPP-4 inhibitor Alogliptin (Nesina, Vipidia), 2013
SGLT-2 inhibitor Dapagliflozin (Farxiga), 2014
SGLT-2 inhibitor Empagliflozin (Jardiance), 2014
GLP-1 receptor agonist Albiglutide (Tanzeum), 2014
GLP-1 receptor agonist Dulaglutide (Trulicity), 2014
Inhaled insulin powder Afrezza, 2014

Advertisement


Insulins

There are different types of insulin depending on how quickly they work, when they peak a maximum strength, and how long they work.

Generic Brand Name
Rapid Acting Insulins
Insulin aspart Novolog
Insulin glulisine Apidra
Insulin lispro Humalog
Insulin human Afrezza Inhalation Powder
Short Acting Insulins
Regular insulin Humulin R, Novolin R
Intermediate Acting Insulins
Insulin NPH Hagedorn NPH , Humulin N, Novolin N
Long Acting Insulins
Insulin detemir Levemir
Insulin glargine Lantus
Premixed Insulins
Insulin aspart protamine/
insulin aspart
NovoLog 50/50, NovoLog 70/30
Insulin lispro protamine/
insulin lispro
Humalog 50/50, Humalog 75/25
Combination with Insulins
Insulin glargine /Lixisenatide Soliqua 100/33
Insulin degludec/Liraglutide Xultophy 100/3.6

Sensitizers

Sensitizers increase the sensitivity of target organs to insulin.

Biguanides

Biguanides improve peripheral glucose uptake and utilization.

Generic Brand Name
Metformin Glucophage, Glucophage XR, Glumetza, Riomet, Fortamet

Phenformin and Buformin where withdrawn due to lactic acidosis risk.

Thiazolidinediones (Glitazones)

Thiazolidinediones work through the improvement of insulin sensitivity by acting on adipose, muscle, and liver to increase glucose utilization and decrease glucose production.

Generic Brand Name
Rosiglitazone Avandia
Pioglitazone Actos

Secretagogues

Secretagogues increase insulin secretion by the pancreas.

Sulfonylureas

Sulfonylureas stimulate insulin release by inhibiting the KATP channel of the pancreatic beta cells. Sulfonylureas are useful only in Type II diabetes, as they work by stimulating endogenous release of insulin.

Generic Brand Name
First-generation
Acetohexamide Dymelor
Chlorpropamide Diabinese
Tolazamide Tolinase
Tolbutamide Orinase
Second-generation
Glipizide Glucotrol, Minidiab, Glibenese
Glyburide (glibenclamide) Diabeta, Micronase, Glynase, Daonil, Euglycon
Glimepiride Amaryl
Gliclazide Uni Diamicron
Glyclopyramide Deamelin-S
Gliquidone Glurenorm

Meglitinides

Meglitinide derivatives stimulate insulin secretion from pancreatic cells, lowering blood glucose levels.

Generic Brand Name
Nateglinide Starlix
Repaglinide Prandin, NovoNorm


Alpha-Glucosidase Inhibitors

Alpha-glucosidase inhibitors are not technically hypoglycemic agents because they do not have a direct effect on insulin secretion or sensitivity. These medications slow the digestive and absorptive process, preventing postprandial glucose raise.

Generic Brand Name
Acarbose Precose, Glucobay
Miglitol Glyset
Voglibose Basen


Glucagon-Like Peptide 1 (GLP-1) Agonists

GLP-1 analogs decrease both fasting and postprandial blood glucose levels without causing hypoglycemia 3. Also, GLP-1 analogs may promote modest weight loss.

Generic Brand Name
Short-acting GLP-1 analogs
Exenatide Byetta
Lixisenatide Lyxumia, Adlyxin
Long-acting GLP-1 analogs
Liraglutide Victoza
Prolonged-acting GLP-1 analogs
Albiglutide Tanzeum
Dulaglutide Trulicity
Exenatide once weekly Bydureon
Under development
Taspoglutide Phase III clinical trials 4

Dipeptidyl Peptidase-4 Inhibitors (Gliptins)

Dipeptidyl peptidase-4 (DPP-4) inhibitors inhibit DPP-4, the enzyme that inactivates incretin hormones GLP-1 and GIP.

Generic Brand Name
Alogliptin Nesina, Vipidia
Anagliptin Suiny
Linagliptin Trajenta
Saxagliptin Onglyza
Sitagliptin Januvia
Teneligliptin Tenelia
DPP-4 inhibitors under development
Dutogliptin 5  
Gemigliptin 6  


Amylin Analogues

Pramlintide is a synthetic version of the naturally occurring pancreatic peptide amylin. Amylin and pramlintide lower postprandial glucose by lowering postprandial glucagon and delaying gastric emptying. Pramlintide is indicated for y Type 1 and Type 2 diabetics who use insulin.

Generic Brand Name
Pramlintide Symlin

Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitors

SGLT-2 inhibitors is a relatively new drug class for the treatment of type 2 diabetes. SGLT-2 inhibitors block reabsorption of glucose in the kidney. dThe mechanism of action is insulin independent.

Generic Brand Name
Canagliflozin Invokana
Dapagliflozin Forxiga, Farxiga
Empagliflozin Jardiance
SGLT-2 inhibitors under development
Ertugliflozin  
Ipragliflozin  
Remogliflozin etabonate  
Tofogliflozin  

Other Anti-diabetic Drugs
Generic Brand Name
Dopamine agonist
Bromocriptine Parlodel, Cycloset
Bile acid sequestrant
Colesevelam Welchol, Cholestagel, Lodalis

Advertisement


Combinations
Generic Brand Name
Alogliptin + Metformin Kazano
Dapagliflozin + Metformin Xigduo XR
Glipizide + Metformin Metaglip
Glyburide + Metformin Glucovance
Linagliptin + Metformin Jentadueto
Pioglitazone + Metformin Actoplus Met, Actoplus Met XR
Repaglinide + Metformin Prandimet
Rosiglitazone + Metformin Avandamet
Saxagliptin + Metformin Kombiglyze XR
Sitagliptin + Metformin Janumet
Rosiglitazone + Glimepiride Avandaryl
Pioglitazone + Glimepiride Duetact
Alogliptin + Pioglitazone Oseni
Simvastatin + Sitagliptin Juvisync
Empagliflozin + Metformin Synjardy

Resources
  • 1. New FDA Approved Drugs CenterWatch
  • 2. David A. Williams. Foye's Medicinal Chemistry. 7th Ed; LWW, 2012
  • 3. Cho YM, Wideman RD, Kieffer TJ. Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. Endocrinol Metab (Seoul). 2013 Dec;28(4):262-74. Full text
  • 4. Rosenstock J, Balas B, Charbonnel B, Bolli GB, Boldrin M, Ratner R, Balena R; T-emerge 2 Study Group. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes. Diabetes Care. 2013 Mar. PubMed
  • 5. Pattzi HM, Pitale S, Alpizar M, Bennett C, O'Farrell AM, Li J, Cherrington JM, Guler HP; PHX1149-PROT202 Study Group. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55. PubMed
  • 6. Kim SH, Lee SH, Yim HJ. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry. Arch Pharm Res. 2013 Oct;36(10):1185-8. PubMed

Created: December 27, 2014
Last updated: February 08, 2017

Advertisement

Home | Contact Us | Cookies Policy

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here



Copyright 2007-2017 eMedExpert.com. All rights reserved.
All information is for educational purposes only.